Brief: Telix Pharmaceuticals Announces FDA Fast Track For BiPASS Pre Biopsy Prostate Imaging
30/09/2026 02:36
BRIEF-Telix Pharmaceuticals Announces FDA Fast Track For BiPASS Pre Biopsy Prostate Imaging Sept 30 (Reuters) - Telix Pharmaceuticals Limited TLX.AX:
FDA FAST TRACK FOR BIPASS PRE BIOPSY PROSTATE IMAGING
ILLUCCIX AND GOZELLIX APPROVED FOR PET IMAGING OF PSMA-POSITIVE PROSTATE CANCER LESIONS
Further company coverage: TLX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telix Pharmaceuticals
See all newsJefferies cuts price target on Telix Pharmaceuticals following quarterly update
Australia's Telix Pharmaceuticals slides on sequential fall in quarterly revenue
Brief: Telix Pharmaceuticals Limited Reports Qtrly Group Revenue Of $245 Million
Education Agreement To Advance Psma-Informed Prostate Care
Australia's Telix rises after dosing first US patients with brain cancer imaging drug